Delivery Order SPE2DB20D2104-SPE2DB25FMXUS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,322.94 to AmerisourceBergen Drug Corp for Spiriva Respimat 1.25 mcg inhaler (4 grams) on August 13, 2025, with completion scheduled for August 14, 2025. This firm fixed price delivery order represents a non-competitive set-aside procurement and reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical supply chain. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Spiriva Respimat 2.5 mcg inhaler (4 grams) with a ceiling value of $1,629.61. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The contract is scheduled for completion by September 15, 2025, with fulfillment from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Spiriva Respimat 2.5 mcg inhalation medication in a 4-gram formulation. This competitively awarded, non-set-aside contract carries a ceiling value of $2,680.75 and a firm fixed price structure, with an ultimate completion date of September 9, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where...
- On August 18, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $1,188.66 to AmerisourceBergen Drug Corp for Spiriva Respimat 2.5 mcg inhalation solution (4 gm). This firm fixed-price contract, with an ultimate completion date of August 19, 2025, is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Spiriva Respimat 2.5 mcg inhalation medication in 4 gm units. This firm fixed price delivery order, valued at $2,640.52, is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The order is scheduled for completion by September 5, 2025, with performance at the company's...
- The Defense Logistics Agency awarded a $3,470.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Spiriva Respimat 1.25 mcg inhalation medication in 4-gram quantities. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), was competitively awarded with no set-aside designation. Performance will be completed at the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,107.10 to AmerisourceBergen Drug Corp on August 6, 2025, for Spiriva Respimat 1.25 mcg inhaler 4gm, a respiratory medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, is scheduled for completion by August 7, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The order represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Spiriva Respimat 1.25 mcg inhaler (4 grams) with a ceiling value of $4,633.86. This firm fixed price, non-set-aside delivery order is scheduled for completion by September 12, 2025, and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal healthcare systems. The work will be performed at the company's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,780.40 to AmerisourceBergen Drug Corp for the supply of Spiriva Respimat 1.25 mcg inhalation medication in 4-gram quantities. This non-set-aside, firm fixed price delivery order was competitively awarded and has an ultimate completion date of August 19, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for SPIRIVA RESPIMAT 1.25 mcg inhalation solution (4 gm) on July 22, 2025, with a ceiling value of $2,903.48. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded procurement. The order is set for completion by July 23, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXUSDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Spiriva Respimat 2.5 mcg inhalation medication in 4-gram quantities, with a ceiling value of $1,277.09. This firm fixed-price delivery order, which must be completed by August 15, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement that extends through December 2026 and provides comprehensive pharmaceutical and medical supply support to military healthcare systems worldwide. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medications, vaccines, and medical devices across multiple therapeutic domains to support Department of Defense and other federal healthcare customers. The company's substantial contract portfolio with DLA demonstrates its established capability to meet federal procurement requirements for pharmaceutical products serving military medical operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/14/25 |